Hakkımızda İletişim Etkileşimler: 118 620
Ada göre bir ilaç arayın

Heparin and Dextrose ve Trombositopeni

Heparin and Dextrose ilacının Trombositopeni hastalığı ile etkileşiminin güvenlik kontrolünün sonucu.

Kontrolün sonucu:
Heparin and Dextrose <> Trombositopeni
Güncellik: 23.07.2019 Eleştirmen: MD PHD P.M. Shkutko, in

Drugs.com, Rxlist.com, Webmd.com, Medscape.com gibi yetkili kaynaklara dayalı kontrolün sonucunda bu ilacın bu komorbid hastalık ile etkileşmesi halinde zarar verebilen veya olumsuz etkisini artırabilen kontrendikasyonlar veya yan etkiler bulundu.

Tüketici:

Heparin kullanımı ciddi trombositopeni olan hastalarda kullanılmamalıdır. Akut trombositopeni heparin alan hastalarda %30'a kadar bildirilen bir risk olabilir. Trombosit sayısı önce ve periyodik olarak heparin sırasında elde edilen, 5 günden daha uzun bir süre için verilen heparin floş çözümleri düzenli ve tekrar kullanımı da dahil edilmelidir. 100.000/mm3 yukarıdaki sayıları ile hafif trombositopeni ters devam heparin rağmen kararlı kalabilecek. Ancak, herhangi bir derecede trombositopeni yakından takip edilmelidir. Eğer tedavi sayısı 100.000 altında gerekirse hastaların total/veya tekrarlayan tromboz gelişirse, alternatif, (örneğin, argatroban, bivalirudin, lepirudin) nonheparin antikoagülan uygulanan düşerse kesilmelidir. (HİT), Heparin kaynaklı trombositopeni trombosit ve geri toplama kaynaklanan ciddi bir antikor-aracılı reaksiyon. HİT venöz ve arteryel tromboz gelişimi için ilerleme olabilir, bir durum için heparin (HİTT)-trombositopeni ve tromboz olarak anılacaktır. Trombotik olaylar da HİTT ilk sunumu olabilir ve amputasyon yol açabilir, ve muhtemelen ölüm olabilir ekstremite derin ven trombozu, pulmoner emboli, serebral tromboz, ekstremite iskemisi, inme, miyokard infarktüsü, mezenterik tromboz, renal arter trombozu, cilt nekrozu, gangren olabilir. İkisi de vuruldu ve HİTT, heparin tedavisi kesildikten sonra ortaya birkaç hafta geçebilir. Trombositopeni ve tromboz ile heparin kesildikten sonra başvuran hastalarda VURDU ve HİTT için değerlendirilmelidir. Bir bölüm sonrasında, heparin gelecekteki her türlü kullanımını kaçınılmalıdır, ve düşük moleküler ağırlıklı heparin kullanımı HİT antikoru ile çapraz Reaktivite potansiyeli düşünün, aksi takdirde kullanılmamalıdır aşırı dikkatle ele alınmalıdır.

Kaynaklar
  • Warkentin TE, Hirsh J, Kelton JG "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995): 1007
  • Kelton JG, Sheridan D, Santos A, et al "Heparin-induced thrombocytopenia: laboratory studies." Blood 72 (1988): 925-30
  • Magnani HN "Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost 1993 Dec 20;70(6):1072]." Thromb Haemost 70 (1993): 554-61
  • Berkowitz N, Beckman J "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995): 1006
  • Kleinschmidt S, Seyfert UT "Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice." Angiology 46 (1995): 37-44
  • Cines DB, Kaywin P, Bina M, et al "Heparin-associated thrombocytopenia." N Engl J Med 303 (1980): 788-95
  • Rissieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996): 157
  • Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991): 1425-6
  • Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995): 736-8
  • Platell CF, Tan EG "Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions." Aust N Z J Surg 56 (1986): 621-3
  • Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T "Heparin-induced thrombocytopenia in hemodialysis patients." Am J Kidney Dis 28 (1996): 82-5
  • Hougardy N, Machiels JP, Ravoet C "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995): 1007
  • "Product Information. Orgaran (danaparoid)." Organon, West Orange, NJ.
  • Lecompte T, Luo SK, Stieltjes N, Lecrubier C, et al "Thrombocytopenia associated with low-molecular-weight heparin." Lancet 338 (1991): 1217
  • Bell WR, Royall RM "Heparin-associated thrombocytopenia: a comparison of three heparin preparations." N Engl J Med 303 (1980): 902-7
  • Chong BH, Magnani HN "Orgaran in heparin-induced thrombocytopenia." Haemostasis 22 (1992): 85-91
  • Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986): 11-8
  • Tezcan AZ, Tezcan H, Gastineau DA, Armitage JO, Haire WD "Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases." Bone Marrow Transplant 14 (1994): 487-90
  • Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, Bassand JP "Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia." Am J Hematol 50 (1995): 20-5
  • Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996): 329-30
  • Bleasel JF, Rasko JE, Rickard KA, Richards G "Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome." Med J Aust 157 (1992): 192-3
  • Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989): 415-8
  • Rice P, Dace S, Mcmullin MF, Clements WDB "Heparin induced thrombocytopenia causing life-threatening postoperative haemorrhage." Br J Clin Pract 50 (1996): 404-5
  • Warkentin TE, Hayward CP, Smith CA, et al "Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia." J Lab Clin Med 120 (1992): 371-9
  • Gruel Y, Lang M, Darnige L, Pacouret G, Dreyfus X, Leroy J, Charbonnier B "Fatal effect of re-exposure to heparin after previous heparin- associated thrombocytopenia and thrombosis ." Lancet 336 (1990): 1077-8
  • Slocum MM, Adams JG, Teel R, Spadone DP, Silver D "Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome." J Vasc Surg 23 (1996): 839-43
  • Shumate MJ "Heparin-induced thrombocytopenia." N Engl J Med 333 (1995): 1006-7
  • Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996): 211-2
  • Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A "Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia." Eur J Clin Pharmacol 37 (1989): 415-8
  • "Product Information. Lovenox (enoxaparin)." Rhone-Poulenc Rorer, Collegeville, PA.
  • Sandler RM, Seifer DB, Morgan K, Pockros PJ, Wypych J, Weiss LM, Schiffman S "Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG." Am J Clin Pathol 83 (1985): 760-4
  • Force RW "Heparin-induced thrombocytopenia." Am J Health Syst Pharm 52 (1995): 2528
  • Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995): 1330-5
  • Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996): 157
  • Kikta MJ, Keller MP, Humphrey PW, Silver D, Towne JB, Tsapogas M "Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?" Surgery 114 (1993): 705-10
  • Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994): 61-3
  • Chong BH "Heparin-induced thrombocytopenia." Aust N Z J Med 22 (1992): 145-52
  • Munver R, Schulman IC, Wolf DJ, Rosengart TK "Heparin-induced thrombocytopenia and thrombosis: presentation after cardiopulmonary bypass." Ann Thorac Surg 58 (1994): 1764-6
  • "Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company, Indianapolis, IN.
Heparin and Dextrose

Jenerik adı: heparin

Marka adı: Hep-Pak, Heparin Lock flush, Hep-Pak CVC, Hep-Lock, Heparin Sodium ADD-Vantage, HepFlush

Eşdeğer ilaçlar: Heparin Injection, Heparin

Gıda ve yaşam tarzı ile etkileşim
Ilaç etkileşimlerini